Home » VOYAGER'S ALZHEIMER'S TREATMENT SHOWS PROMISE
VOYAGER'S ALZHEIMER'S TREATMENT SHOWS PROMISE
VP4896, Voyager Pharmaceutical's lead product, has shown promise in a Phase II clinical trial, the company reported.
Leuprolide acetate, the active ingredient in VP4896, stabilized the cognitive and functional decline of women with mild-to-moderate Alzheimer's disease when used in conjunction with standard Alzheimer's therapy, the company said.
Leuprolide acetate has been used for over 20 years as a treatment for prostate cancer.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May